Navigation Links
Effective pain treatment for cancer patients?
Date:6/25/2009

Cancer patients often suffer from severe pain that cannot be effectively treated with conventional medication. Researchers at the Pharmacology Institute of the University of Heidelberg have found the possible reasons for this tumors release two signal substances that make nerve cells especially sensitive and enhance tumor growth. In animal tests, when the researchers blocked the effect of the signal substances on the nerve cells, the sensitivity of the nerve cells and tumor growth were reduced.

The results of the research of the international working group headed by Professor Dr. Rohini Kuner indicate a new approach for the development of effective pain medication for cancer patients. The work has now been published online in the prestigious journal Nature Medicine.

Tumor pain: new therapies are urgently needed

For patients, severe pain is one of the worst and most feared symptoms of cancer. The causes of the frequently extreme pain are still largely unknown. Cancer pain is frequently difficult to handle with conventional pain medication such as opioids. High dosages are required to achieve any effect at all as a result, the side effects are immense for the patients and tolerance may quickly ensue. "There is a great need for special pain medication for cancer patients," says pharmacologist Professor Dr. Rohini Kuner, who is especially interested in explaining the mechanisms of chronic pain.

Tumor signals make nerve cells extremely sensitive to pressure

In this research project, she and her colleagues examined tissue from mice to determine what signal substances were released by tumors. They discovered two molecules that were previously known only as growth factors for blood-forming stem cells. Contact with these molecules made nerve cells in the vicinity of the cancer tissue considerably more sensitive to pressure, as the researchers demonstrated by testing nerve activity with electrodes. "The findings are consistent with descriptions of cancer patients who say that merely touching the affected area is painful," explained Professor Dr. Kuner.

But not just touching, even tumor growth itself causes pain, for the expanding tissue also exerts pressure. The cancer cells apparently use the growth factors for their own growth and spread through the nerve pathways and blood vessels to the rest of the organism.

An injection against tumor pain?

The discovery made in Heidelberg opens up new prospects in the fight against cancer pain in the next step, the researchers injected proteins (antibodies) that block the contact sites for cancer signal substances on the nerve cells. Indeed, the sensitivity of nerve cells and tumor growth were reduced.

Further research must now show whether this use is also possible in human tissue. If so, it would be conceivable to inject these "protein blockers" directly into the tumor and thus reduce pain and side effects for the patient.


'/>"/>

Contact: Dr. Rohini Kuner
rohini.kuner@pharma.uni-heidelberg.de
49-622-154-8289
University Hospital Heidelberg
Source:Eurekalert  

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. Use of certain lipid measures not more effective in predicting coronary heart disease
3. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
4. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
5. Stanford study highlights cost-effective method of lowering heart disease risks
6. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
7. Case Management Cost-Effective Way to Cut Heart Risks
8. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
9. Nasal Anthrax Vaccine Proves Effective in Animal Study
10. Family-based treatment more effective than supportive psychotherapy in treating bulimia
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Effective pain treatment for cancer patients?
(Date:8/16/2017)... ... August 16, 2017 , ... An August 3rd article on Reuters covers ... of a report in JAMA (the Journal of the American Medical Association). The study found ... to achieve BMIs under 30, when compared to patients with lower BMIs. At present, weight ...
(Date:8/16/2017)... GA (PRWEB) , ... August 16, 2017 , ... ... new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... list represents a unique look at the most successful companies within the American economy’s ...
(Date:8/16/2017)... Brentwood, TN (PRWEB) , ... August 16, 2017 ... ... market-leading dermatology practice partnerships through affiliations and de novo development, today announced ... practice. , Cumberland Skin Surgery and Dermatology, with offices in both Hermitage ...
(Date:8/16/2017)... ... 16, 2017 , ... Paul Vitenas, MD, FACS , is honored to ... annual list identifies the nation’s top physicians, in a variety of specialties. This marks ... top of Castle Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of Infection Control ... cycle, both between patient procedures and before storage, is a requisite practice crucial ... to the prevention of disease transmission and nosocomial infection as cleaning and HLD.” ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... president, effective Aug. 7, 2017. ... other interests and will serve as president emeritus during a ... us in multiple leadership roles since he joined Diplomat with ... has provided decisive, strategic leadership which continues to benefit our ...
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology: